Tocilizumab: Efficacy and Tolerance in Rheumatoid Arthritis in Current Practice
PDF

How to Cite

1.
Akasbi N, Mounir A, Omboumahou Bakale FE, El Fakir S, Harzy T. Tocilizumab: Efficacy and Tolerance in Rheumatoid Arthritis in Current Practice. Integr J Med Sci [Internet]. 2019Apr.26 [cited 2020Feb.23];6. Available from: https://mbmj.org/index.php/ijms/article/view/ijms.v6ir.253

Abstract

Introduction: The aim of this study was to evaluate in “real life” the efficacy and the tolerance of Tocilizumab (TCZ) in the treatment of rhumatoide arthritis (RA).
Materials and methods: A cross-sectional study including patients with RA patients treated with TCZ at the commended dose of 8 mg/kg/ 4 weeks. The therapeutic response was evaluated by the EULAR DAS 28 ‐CRP/ VS at month 3 and month 6 of treatment.
Results: RA was in most cases severe (76,5 %), seropositive (88,2 %) and erosive (81,3 %). TCZ was prescribed as an alternative to a previous biotherapy in 23 % of the patients and in monotherapy in 76, 5 % of the patients. After treatment follow-up at 3 and 6 months, the different parameters observed were significantly improved including: VAS (visual analogue scale) pain (p=0,000), CRP (mg/L) p=0,000), ESR (mmH1) (p=0,000), DAS 28 CRP (p=0,000), and DAS 28 ESR (p=0,000). Apart from a worsening of renal function in a patient contraindicated continuation of tocilizumab, no serious side effects were noted.
Conclusion: Our study confirmed the efficacy and tolerance of TCZ therapy in Moroccan patients suffering from RA.
Key words: rheumatoid arthritis, tocilizumab, efficacy, tolerance

https://doi.org/10.15342/ijms.v6ir.253
PDF
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2019 Nessrine Akasbi et al.